HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) and maintains a $40 price target.
March 01, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics maintains a Buy rating and a $40 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $40 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100